Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy.
about
Exploring the mechanisms of renoprotection against progressive glomerulosclerosis.Aliskiren, the first direct renin inhibitor: assessing a role in pediatric hypertension and kidney diseases.Comparison of once-daily versus twice-daily dosing of valsartan in patients with chronic stable heart failureDiabetic nephropathy - complications and treatment.ACE inhibitors and AT-1-receptor antagonists COOPERATE in non-diabetic renal disease.Recent advances in diabetic nephropathyCan dual blockade of the renin-angiotensin system reduce progression of kidney disease beyond monotherapy?A pilot study on the effect of telmisartan & ramipril on 24 h blood pressure profile & dipping pattern in type 1 diabetes patients with nephropathy.Resistance of dialyzed patients to erythropoietin.Fixed combination therapy of hypertension: focus on valsartan/hydrochlorothiazide combination (Diovan/HCT).Angiotensin II receptor blockers: the importance of dose in cardiovascular and renal risk reduction.The renal protective effects of angiotensin II receptor blockers in type 2 diabetes mellitus.Implications of albuminuria on kidney disease progression.Antioxidants in kidney diseases: the impact of bardoxolone methyl.Diabetic nephropathy: the proteinuria hypothesis.Differential effects of antihypertensive drugs on renal and glomerular hemodynamics and injury in the chronic nitric-oxide-suppressed rat.Physiology of the Renal Interstitium.Inhibition of the renin-angiotensin system and cardio-renal protection: focus on losartan and angiotensin receptor blockade.Renin-Angiotensin-Aldosterone System Blockade in Diabetic Nephropathy. Present Evidences.Management strategies for patients with hypertension and diabetes: why combination therapy is critical.Preventing end-stage renal disease in diabetic patients - dual blockade of the renin-angiotensin system (Part II).Combined treatment with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: a review of the current evidence.Efficacy and safety of combined vs. single renin-angiotensin-aldosterone system blockade in chronic kidney disease: a meta-analysis.The role of angiotensin II type 1 receptor blockers in the prevention and management of diabetes mellitus.Rationale for combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor treatment and end-organ protection in patients with chronic kidney disease.Are two better than one? Angiotensin-converting enzyme inhibitors plus angiotensin receptor blockers for reducing blood pressure and proteinuria in kidney diseaseComparison of dual RAAS blockade and higher-dose RAAS inhibition on nephropathy progression.Current possibilities of ACE inhibitor and ARB combination in arterial hypertension and its complications.Review: renal protection by inhibition of the renin-angiotensin-aldosterone system.Potassium handling with dual renin-angiotensin system inhibition in diabetic nephropathy.Pharmacogenomics: a new paradigm to personalize treatments in nephrology patients.Antihypertensive and organ-protective effects of benazepril.Are we ready to use aliskiren in children?Hypertension in diabetic nephropathy: epidemiology, mechanisms, and management.Renoprotective effects of benazepril: current perspective.Combination use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in diabetic kidney disease.Vascular Impairment of Epineurial Arterioles of the Sciatic Nerve: Implications for Diabetic Peripheral Neuropathy.Role of the renin angiotensin system in diabetic nephropathy.Effect of spironolactone on urinary protein excretion in patients with chronic kidney disease.Renin-angiotensin system blockade prevents the increase in plasma transforming growth factor beta 1, and reduces proteinuria and kidney hypertrophy in the streptozotocin-diabetic rat.
P2860
Q30499205-0C23455A-697E-4C80-BDF0-830F099C019AQ33756874-C4E744D2-FE66-44D7-8DCB-6CC841302B9EQ34068712-3EFBEE32-1E93-4820-9734-ABC2F93B6C2BQ34387952-99742487-2576-4B1E-93D7-FDC3BB099A5BQ35164724-32731A4F-37E1-415F-9FA2-5B92A2C05E61Q35520625-855C5F5D-BB46-4399-B5FE-4824E6291744Q35609741-774B8495-86C4-444A-8EA0-634113AAAD45Q35646901-4B2C280E-B206-46B9-84BC-BBAADCA81780Q35694046-167E55B1-AFAE-4854-9F91-DA873C6A6EA8Q35696255-40302311-5EA3-43CD-9924-BF4D0DEF190FQ35799000-87207E1C-5D30-4F8F-B3CC-6DE920322D66Q35880931-7CDDEED3-5DC7-41E1-A214-189F7117C0F1Q35945756-47876D28-0764-40D3-B4F8-9CBC34D01727Q36026304-1C27AAB5-F5EA-4A8B-A943-EC89095FAB3AQ36061335-58B69346-77B2-47C0-9904-2EC3B8932D35Q36108475-56B29A31-5CFA-4BF4-9D9A-EB48D7DBF397Q36123584-7EEE6B41-FEEB-477E-8E6D-060D5DCFF863Q36249947-275169B4-5000-4DF7-8841-4994B31F0613Q36329456-28FBAC91-0231-47B0-B606-B6CACCEAE2EAQ36392677-9F41D316-C6B9-4565-812D-2015526DAC26Q36392987-68672A27-1C2F-434D-8A1A-D13FBDEDAB8BQ36480076-0C77C9F0-0D79-4A7D-A4C4-1E0C694D6268Q36764872-D90B0BA3-0CF9-422C-844D-E5647C1133D4Q36909521-6A9E8143-4022-4620-8423-ECF21624DAADQ37029675-5D7EF5B9-9446-4A1B-9453-49E420CEE49BQ37052003-42CD444A-E97F-4AAB-A8BC-AA60C0D63B7FQ37158325-C1F953BD-3E5A-42B1-82E3-18495DE343BAQ37176470-6247D366-2098-4A51-9DA4-C1EF2A2860F8Q37415058-CFE1FE03-1A1A-41CB-8FDE-FE723C116E7BQ37553108-DD96820B-7C8A-4633-AE42-59E62752B5AFQ37646842-F0BB5184-F63B-496C-A369-DDD7F87714DDQ37812376-6C7D3636-D3A8-4378-8105-8A3D560CFD18Q37820390-BC8B4CEC-BD2D-4355-B827-19D2E2BCE277Q37827620-1BD4BB1E-CDA5-401B-865E-AAFA3B513FF8Q37895676-2297BCA9-067A-4A5B-B237-F457317D19A6Q38105019-050A5824-1725-4F62-84CF-5B83D9A70786Q38671591-A2D9D017-A1F8-4653-8856-B782405EBC0CQ42723231-58387E81-7204-4CF2-8BC9-8FBE2D66CF60Q43210222-A253F923-BB3B-4BD7-A525-606FF689BF9EQ45139079-03EDFAB6-C881-4B4C-8FD7-754764EC59D0
P2860
Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Additive effect of ACE inhibit ...... nts with diabetic nephropathy.
@en
Additive effect of ACE inhibit ...... nts with diabetic nephropathy.
@nl
type
label
Additive effect of ACE inhibit ...... nts with diabetic nephropathy.
@en
Additive effect of ACE inhibit ...... nts with diabetic nephropathy.
@nl
prefLabel
Additive effect of ACE inhibit ...... nts with diabetic nephropathy.
@en
Additive effect of ACE inhibit ...... nts with diabetic nephropathy.
@nl
P2093
P1476
Additive effect of ACE inhibit ...... nts with diabetic nephropathy.
@en
P2093
Berit R Jensen
Hans-Henrik Parving
Peter Jacobsen
P304
P356
10.1097/01.ASN.0000054495.96193.BF
P50
P577
2003-04-01T00:00:00Z